Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression
Keiran S.M. Smalley(Moffitt Cancer Center), Katherine L. Nathanson(Translational Therapeutics (United States))
Cited by 97
Related Papers
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
|Cancer Research|2011|546
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
|British Journal of Cancer|2010|313
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
|Nature Communications|2017|308
Dysregulation of Claudin-7 Leads to Loss of E-Cadherin Expression and the Increased Invasion of Esophageal Squamous Cell Carcinoma Cells
|American Journal Of Pathology|2007|134
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
|British Journal of Cancer|2007|105